How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
BACKGROUND
Evidence on sequential trial with atypical antipsychotics has been scarce.


OBJECTIVE
We conducted an algorithm-based antipsychotic pharmacotherapy.


METHODS
In this open-label study, patients with schizophrenia (DSM-IV) were treated with antipsychotic monotherapy, step-by-step, with each trial lasting up to 8 weeks. At baseline, they were highly symptomatic to score more than 54 in the total Brief Psychiatric Rating Scale (BPRS(1-7)) score. When the posttreatment BPRS score was above 70% of the baseline, they were subsequently treated with another and up to three atypicals. Basically, anticholinergics were prohibited, and only adjunctive allowed was lorazepam. The secondary endpoint was a clinical status good enough to be discharged for 66 inpatients and a successful continuation therapy with the same antipsychotic agent for more than 6 months for 12 outpatients.


RESULTS
Three groups of 26 patients each were randomized to Olanzapine, Quetiapine, or Risperidone. Thirty-nine (50%) responded to the first agent (Olanzapine16, Quetiapine9, Risperidone14), and 14 responded to the second. Only two showed response to the third, and 16 failed to respond to all three antipsychotics, with only 7 dropouts. Overall, there were 22 Olanzapine, 14 Quetiapine, and 19 Risperidone responders. Based on the secondary outcome, 20 Olanzapine-treated (average maximum dose, 15.4 mg), 10 Quetiapine-treated (418 mg), and 20 Risperidone-treated (4.10 mg) patients responded. The difference in response as the first choice was significant (p < 0.05). Relative doses of those failing to respond were comparable (Olanzapine 18.3 mg, Quetiapine 564 mg, Risperidone5.47 mg). Extrapyramidal symptoms did not change significantly.


CONCLUSIONS
When the first atypical antipsychotic is inadequate, switching to the second is worth trying, although some remain treatment-refractory. Quetiapine may be inferior to Olanzapine and Risperidone in symptomatic patients.
Suzuki
Takefumi
T
Department of Neuro-Psychiatry, School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. takefumi@oak.dti.ne.jp
Uchida
Hiroyuki
H
Watanabe
Koichiro
K
Nomura
Kensuke
K
Takeuchi
Hiroyoshi
H
Tomita
Masayuki
M
Tsunoda
Kenichi
K
Nio
Shintaro
S
Den
Ryoske
R
Manki
Hiroshi
H
Tanabe
Akira
A
Yagi
Gohei
G
Kashima
Haruo
H
D000328:Adult; D000465:Algorithms; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D018967:Risperidone; D000077152:Olanzapine
J Clin Psychiatry. 2003;64 Suppl 12:2-97, quiz 98-100
14640143
Clin Ther. 2005 Dec;27(12 ):1930-41
16507379
Arch Gen Psychiatry. 1988 Sep;45(9):789-96
3046553
Psychopharmacology (Berl). 2005 Dec;183(3):383-6
16240162
Int Clin Psychopharmacol. 2006 Nov;21(6):369-72
17012984
Schizophr Res. 2002 Oct 1;57(2-3):227-38
12223254
J Clin Psychiatry. 2006 Jul;67(7):1093-103
16889453
Aust N Z J Psychiatry. 2006 May;40(5):437-45
16683970
Int Clin Psychopharmacol. 2003 Nov;18(6):323-9
14571152
Can J Psychiatry. 1997 Feb;42(1):34-43
9040921
Schizophr Bull. 2004;30(2):193-217
15279040
Eur J Clin Pharmacol. 2004 Feb;59(12 ):905-9
14685800
J Psychopharmacol. 2005 Sep;19(5 Suppl):32-8
16144784
J Clin Psychiatry. 2005 Aug;66(8):1021-30
16086618
Psychiatry Res. 2006 Nov 15;144(2-3):177-89
17010448
Schizophr Bull. 2004;30(3):627-47
15631256
Arch Gen Psychiatry. 2003 Jun;60(6):553-64
12796218
J Clin Psychiatry. 2005 Dec;66(12 ):1564-8
16401158
Am J Psychiatry. 2005 Mar;162(3):441-9
15741458
Can J Psychiatry. 2005 Dec;50(14 ):901-8
16494259
N Engl J Med. 2005 Sep 22;353(12 ):1209-23
16172203
J Clin Pharm Ther. 2006 Feb;31(1):57-65
16476121
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):361-9
14751434
Psychopharmacology (Berl). 2005 Sep;181(3):566-75
15991004
J Clin Psychopharmacol. 2006 Dec;26(6):571-8
17110813
Neuropsychopharmacology. 2007 Sep;32(9):1903-10
17287825
J Psychiatr Res. 2006 Oct;40(7):669-76
16762371
J Clin Psychiatry. 2005 Dec;66(12):1512-6
16401150
Int J Neuropsychopharmacol. 2006 Jun;9(3):357-66
16316478
Schizophr Res. 2006 Sep;86(1-3):15-22
16884895
J Clin Psychopharmacol. 2006 Oct;26(5):453-61
16974184
Br J Psychiatry. 1980 May;136:413-20
7388247
J Clin Psychiatry. 2004 Apr;65(4):500-8
15119912
Br J Psychiatry. 2006 Nov;189:433-40
17077434
J Clin Psychiatry. 2006 Sep;67(9):1391-6
17017825
J Clin Psychopharmacol. 2006 Aug;26(4):401-4
16855459
Am J Psychiatry. 2006 Apr;163(4):611-22
16585435
Curr Med Chem. 2004 Feb;11(3):313-27
14965234
Am J Psychiatry. 2006 Apr;163(4):600-10
16585434
Int J Neuropsychopharmacol. 2004 Jun;7(2):133-42
14741059
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):972-82
16023776
J Clin Psychopharmacol. 2006 Jun;26(3):238-49
16702888
Int J Neuropsychopharmacol. 2005 Sep;8(3):457-72
15784157
Can J Psychiatry. 2006 Jul;51(8):480-91
16933585
BMJ. 2000 Dec 2;321(7273):1371-6
11099280